Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Histone deacetylases (HDACs) are crucial epigenetic regulators implicated in various diseases, including cancer.
• Developing targeted HDAC inhibitors requires understanding structure-activity relationships for isoform selectivity.
• N-hydroxybenzamide scaffolds are established pharmacophores for HDAC inhibition.

Purpose of the Study:

• To synthesize and characterize novel N-hydroxybenzamide-based HDAC inhibitors.
• To evaluate the anti-proliferation activity of these compounds against tumor cell lines.
• To investigate the impact of capping group modifications on HDAC isoform selectivity.

Main Methods:

• Synthesis of a library of N-hydroxybenzamide derivatives (compounds 1a-o) with varied branched hydrophobic capping groups.
• In vitro enzymatic assays to determine HDAC inhibition activity.
• Cell-based assays to assess anti-proliferation effects in four human tumor cell lines.
• Selectivity profiling of promising compounds against recombinant human HDAC1 (Class I) and HDAC4 (Class II).

Main Results:

• Novel N-hydroxybenzamide-based HDAC inhibitors (1a-o) were successfully synthesized.
• Compounds demonstrated varying degrees of HDAC inhibition and anti-proliferation activity across tested tumor cell lines.
• Compounds 1j-o exhibited differential selectivity profiles against HDAC1 and HDAC4.
• The chemical nature of the capping group significantly influenced the selectivity between Class I and Class II HDAC isoforms.

Conclusions:

• The study successfully identified novel HDAC inhibitors with potential anti-cancer properties.
• Structural modifications, particularly at the capping group, are critical for achieving selectivity among HDAC isoforms.
• These findings provide valuable insights for the rational design of next-generation HDAC inhibitors with improved therapeutic potential.